 Dopamine Plasma Membrane Transport Proteins
"Dopamine Plasma Membrane Transport Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Sodium chloride-dependent neurotransmitter symporters located primarily on the PLASMA MEMBRANE of dopaminergic neurons. They remove DOPAMINE from the EXTRACELLULAR SPACE by high affinity reuptake into PRESYNAPTIC TERMINALS and are the target of DOPAMINE UPTAKE INHIBITORS.
| Descriptor ID |
D050483
|
| MeSH Number(s) |
D12.776.157.530.450.625.124 D12.776.157.530.562.374.500.500 D12.776.157.530.937.500 D12.776.543.585.450.625.124 D12.776.543.585.562.374.500.500 D12.776.543.585.937.500
|
| Concept/Terms |
Dopamine Plasma Membrane Transport Proteins- Dopamine Plasma Membrane Transport Proteins
- Dopamine Transporter
- Transporter, Dopamine
- SLC6A3 Protein
- Protein, SLC6A3
- Solute Carrier Family 6 (Neurotransmitter Transporter), Member 3 Protein
- Dopamine Transporter Proteins
- Transporter Proteins, Dopamine
- Dopamine Carriers
- Carriers, Dopamine
- DAT Dopamine Transporter Proteins
- Neurotransmitter Transport Proteins, Dopamine-Specific
- Neurotransmitter Transport Proteins, Dopamine Specific
- Neurotransmitter Transporters, Dopamine-Specific
- Dopamine-Specific Neurotransmitter Transporters
- Neurotransmitter Transporters, Dopamine Specific
- Transporters, Dopamine-Specific Neurotransmitter
- DAT Dopamine Transporter
- Dopamine Transporter, DAT
- Transporter, DAT Dopamine
- Dopamine Plasma Membrane Transporter Proteins
|
Below are MeSH descriptors whose meaning is more general than "Dopamine Plasma Membrane Transport Proteins".
Below are MeSH descriptors whose meaning is more specific than "Dopamine Plasma Membrane Transport Proteins".
This graph shows the total number of publications written about "Dopamine Plasma Membrane Transport Proteins" by people in this website by year, and whether "Dopamine Plasma Membrane Transport Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 3 | 3 | | 2005 | 1 | 0 | 1 | | 2007 | 1 | 0 | 1 | | 2008 | 1 | 1 | 2 | | 2009 | 3 | 0 | 3 | | 2011 | 1 | 0 | 1 | | 2012 | 2 | 0 | 2 | | 2013 | 1 | 0 | 1 | | 2014 | 0 | 3 | 3 | | 2015 | 1 | 2 | 3 | | 2017 | 0 | 2 | 2 | | 2018 | 2 | 0 | 2 | | 2019 | 0 | 1 | 1 | | 2020 | 2 | 0 | 2 | | 2021 | 0 | 1 | 1 | | 2022 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Dopamine Plasma Membrane Transport Proteins" by people in Profiles.
-
Patterson CG, Joslin E, Gil AB, Spigle W, Nemet T, Chahine L, Christiansen CL, Melanson E, Kohrt WM, Mancini M, Josbeno D, Balfany K, Griffith G, Dunlap MK, Lamotte G, Suttman E, Larson D, Branson C, McKee KE, Goelz L, Poon C, Tilley B, Kang UJ, Tansey MG, Luthra N, Tanner CM, Haus JM, Fantuzzi G, McFarland NR, Gonzalez-Latapi P, Foroud T, Motl R, Schwarzschild MA, Simuni T, Marek K, Naito A, Lungu C, Corcos DM. Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial. Trials. 2022 Oct 06; 23(1):855.
-
Lloyd JT, Yee AG, Kalligappa PK, Jabed A, Cheung PY, Todd KL, Karunasinghe RN, Vlajkovic SM, Freestone PS, Lipski J. Dopamine Dysregulation and Altered Responses to Drugs Affecting Dopaminergic Transmission in a New Dopamine Transporter Knockout (DAT-KO) Rat Model. Neuroscience. 2022 05 21; 491:43-64.
-
Schwarzschild MA, Ascherio A, Casaceli C, Curhan GC, Fitzgerald R, Kamp C, Lungu C, Macklin EA, Marek K, Mozaffarian D, Oakes D, Rudolph A, Shoulson I, Videnovic A, Scott B, Gauger L, Aldred J, Bixby M, Ciccarello J, Gunzler SA, Henchcliffe C, Brodsky M, Keith K, Hauser RA, Goetz C, LeDoux MS, Hinson V, Kumar R, Espay AJ, Jimenez-Shahed J, Hunter C, Christine C, Daley A, Leehey M, de Marcaida JA, Friedman JH, Hung A, Bwala G, Litvan I, Simon DK, Simuni T, Poon C, Schiess MC, Chou K, Park A, Bhatti D, Peterson C, Criswell SR, Rosenthal L, Durphy J, Shill HA, Mehta SH, Ahmed A, Deik AF, Fang JY, Stover N, Zhang L, Dewey RB, Gerald A, Boyd JT, Houston E, Suski V, Mosovsky S, Cloud L, Shah BB, Saint-Hilaire M, James R, Zauber SE, Reich S, Shprecher D, Pahwa R, Langhammer A, LaFaver K, LeWitt PA, Kaminski P, Goudreau J, Russell D, Houghton DJ, Laroche A, Thomas K, McGraw M, Mari Z, Serrano C, Blindauer K, Rabin M, Kurlan R, Morgan JC, Soileau M, Ainslie M, Bodis-Wollner I, Schneider RB, Waters C, Ratel AS, Beck CA, Bolger P, Callahan KF, Crotty GF, Klements D, Kostrzebski M, McMahon GM, Pothier L, Waikar SS, Lang A, Mestre T. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA. 2021 09 14; 326(10):926-939.
-
Schacht JP, Hoffman M, Chen BH, Anton RF. Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial. Pharmacogenomics J. 2022 02; 22(1):1-8.
-
Chahine LM, Brumm MC, Caspell-Garcia C, Oertel W, Mollenhauer B, Amara A, Fernandez-Arcos A, Tolosa E, Simonet C, Hogl B, Videnovic A, Hutten SJ, Tanner C, Weintraub D, Burghardt E, Coffey C, Cho HR, Kieburtz K, Poston KL, Merchant K, Galasko D, Foroud T, Siderowf A, Marek K, Simuni T, Iranzo A. Dopamine transporter imaging predicts clinically-defined a-synucleinopathy in REM sleep behavior disorder. Ann Clin Transl Neurol. 2021 01; 8(1):201-212.
-
Anton RF, Voronin KE, Book SW, Latham PK, Randall PK, Glen WB, Hoffman M, Schacht JP. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial. Alcohol Clin Exp Res. 2020 10; 44(10):2084-2096.
-
Buck JM, Sanders KN, Wageman CR, Knopik VS, Stitzel JA, O'Neill HC. Developmental nicotine exposure precipitates multigenerational maternal transmission of nicotine preference and ADHD-like behavioral, rhythmometric, neuropharmacological, and epigenetic anomalies in adolescent mice. Neuropharmacology. 2019 05 01; 149:66-82.
-
Kaiser RH, Treadway MT, Wooten DW, Kumar P, Goer F, Murray L, Beltzer M, Pechtel P, Whitton A, Cohen AL, Alpert NM, El Fakhri G, Normandin MD, Pizzagalli DA. Frontostriatal and Dopamine Markers of Individual Differences in Reinforcement Learning: A Multi-modal Investigation. Cereb Cortex. 2018 12 01; 28(12):4281-4290.
-
Schacht JP, Anton RF, McNamara PJ, Im Y, King AC. The dopamine transporter VNTR polymorphism moderates the relationship between acute response to alcohol and future alcohol use disorder symptoms. Addict Biol. 2019 09; 24(5):1109-1118.
-
Schacht JP, Voronin KE, Randall PK, Anton RF. Dopaminergic Genetic Variation Influences Aripiprazole Effects on Alcohol Self-Administration and the Neural Response to Alcohol Cues in a Randomized Trial. Neuropsychopharmacology. 2018 05; 43(6):1247-1256.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|